Medical Therapy to Prevent or Slow Progression of Aortic Stenosis: Current Evidence and Future Directions

Travis Chong; Nick S R Lan; William Courtney; Albert He; Geoff Strange; David Playford; Girish Dwivedi; Graham S Hillis; Abdul Rahman Ihdayhid

doi:10.1097/CRD.0000000000000528

Medical Therapy to Prevent or Slow Progression of Aortic Stenosis: Current Evidence and Future Directions

Cardiol Rev. 2023 Mar 24. doi: 10.1097/CRD.0000000000000528. Online ahead of print.

Authors

Travis Chong^{1

2}, Nick S R Lan^{1

2

3}, William Courtney^{3

4}, Albert He^{1

2}, Geoff Strange⁵, David Playford⁵, Girish Dwivedi^{1

2

3}, Graham S Hillis^{3

4}, Abdul Rahman Ihdayhid^{1

2

6}

Affiliations

¹ From the Department of Cardiology, Fiona Stanley Hospital, Perth, Australia.
² Harry Perkins Institute of Medical Research, Perth, Australia.
³ Internal Medicine, Medical School, The University of Western Australia, Perth, Australia.
⁴ Department of Cardiology, Royal Perth Hospital, Perth, Australia.
⁵ School of Medicine, University of Notre Dame, Fremantle, Australia; and.
⁶ Curtin Medical School, Curtin University, Perth, Australia.

PMID: 36961371
DOI: 10.1097/CRD.0000000000000528

Abstract

Degenerative aortic stenosis is a growing clinical problem owing to the high incidence in an aging population and its significant morbidity and mortality. Currently, aortic valve replacement remains the only treatment. Despite promising observational data, pharmacological management to slow or halt progression of aortic stenosis has remained elusive. Nevertheless, with a greater understanding of the mechanisms which underpin aortic stenosis, research has begun to explore novel treatment strategies. This review will explore the historical agents used to manage aortic stenosis and the emerging agents that are currently under investigation.